10-KPeriod: FY2008

ABBOTT LABORATORIES Annual Report, Year Ended Dec 31, 2008

Filed February 20, 2009For Securities:ABT

Summary

Abbott Laboratories' 2008 10-K filing reflects a company navigating growth through strategic acquisitions and product development amidst a dynamic healthcare landscape. The company reported strong sales growth, driven significantly by its Pharmaceutical Products segment, particularly the blockbuster drug Humira, which saw a substantial increase in worldwide sales. Abbott also demonstrated a commitment to expanding its portfolio through strategic acquisitions, notably announcing the agreement to acquire Advanced Medical Optics (AMO) for $2.8 billion in early 2009, reinforcing its focus on higher-growth segments. Despite economic headwinds, Abbott maintained robust operating performance and cash flow from operations. The company highlighted its ongoing investment in research and development, with a substantial portion dedicated to key therapeutic areas and pipeline programs like Humira's new indications. However, like many in the pharmaceutical sector, Abbott faces challenges from generic competition for some of its products, such as Depakote and Omnicef, which have impacted sales in those specific areas. The company also addressed various legal proceedings and government regulations as part of its risk factor disclosures, emphasizing compliance and risk management strategies.

Financial Highlights

53 data points
Beta

Revenue

$29.53B

57.3% Gross Margin

Net Income

$4.88B

16.5% Net Margin

EPS (Diluted)

$3.12

Total Assets

$42.42B

Cash & Equivalents

$4.11B

Free Cash Flow

$5.71B

Financial Statements
Beta
Revenue$29.53B
Cost of Revenue$12.61B
Gross Profit$16.92B
SG&A Expenses$8.44B
Operating Expenses$23.83B
Operating Income$5.69B
Interest Expense$528.47M
Net Income$4.88B
EPS (Basic)$3.16
EPS (Diluted)$3.12
Shares Outstanding (Basic)1.55B
Shares Outstanding (Diluted)1.56B

Key Highlights

  • 1Abbott Laboratories reported strong sales growth, driven by its Pharmaceutical Products segment, with Humira sales reaching $4.5 billion in 2008.
  • 2The company announced a significant strategic acquisition of Advanced Medical Optics (AMO) for approximately $2.8 billion, expected to close in Q1 2009.
  • 3Net cash from operating activities of continuing operations was robust at $7.0 billion in 2008, indicating strong operational performance.
  • 4Research and development expenses remained high, totaling $2.7 billion in 2008, demonstrating a commitment to innovation and pipeline development.
  • 5The company experienced generic competition for products like Depakote and Omnicef, leading to decreased sales in those specific product lines.
  • 6Abbott is actively managing its debt, with long-term debt ratings of AA by Standard & Poor's and A1 by Moody's, and has access to significant credit lines.
  • 7The company continues to invest in its Nutritional, Diagnostic, and Vascular product segments, seeking to capitalize on growth opportunities within these areas.

Frequently Asked Questions

Abbott's sales growth in 2008 was primarily driven by its Pharmaceutical Products segment, with Humira being a major contributor. The acquisitions of Kos Pharmaceuticals Inc. and Guidant's vascular businesses in previous years also continued to bolster sales across various segments. The conclusion of the TAP Pharmaceutical Products Inc. joint venture and the subsequent inclusion of Lupron's U.S. results also contributed to the reported sales figures starting in May 2008.

Abbott acknowledges the impact of generic competition on products like Omnicef and Biaxin, which have seen declining sales. The company also notes the onset of generic competition for Depakote in the latter half of 2008. Abbott's strategy involves continued investment in R&D to develop new products and indications for existing drugs like Humira, and optimizing its product portfolio to mitigate the effects of patent expirations and generic market entry.

The announced acquisition of AMO for approximately $2.8 billion highlights Abbott's strategic intent to expand into higher-growth segments of the healthcare market, specifically vision care technologies. With AMO's annual sales exceeding $1 billion, this acquisition is expected to further diversify Abbott's revenue streams and leverage demographic shifts driving demand for vision care solutions.

Abbott financed its significant acquisitions, such as Kos Pharmaceuticals and Guidant's vascular businesses, primarily through debt, leading to an increase in long-term debt. The company's R&D spending remained substantial in 2008 at $2.7 billion, reflecting a continued commitment to innovation. Despite these investments and the economic environment, Abbott maintained strong operating cash flows and had readily available financial resources, indicating a solid financial position. The company's long-term debt ratings remained strong.